Discover how OS Therapies' immunotherapy, OST-HER2, originally developed for canine osteosarcoma, shows promising results in fast-tracking treatments for human osteosarcoma. Learn about comparative ...
The complex tumor microenvironment (TME) in osteosarcoma is emerging as a critical factor in disease progression and treatment resistance. Recent insights highlight the intricate interplay between ...
NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today provided a ...
Researchers working on a groundbreaking project that could transform how doctors detect and treat osteosarcoma, a rare but ...
Please provide your email address to receive an email when new articles are posted on . Inherited mutations in SMARCAL1 are significantly linked to osteosarcoma risk, an analysis of DNA damage repair ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback